Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation

Leukemia and Lymphoma

Volumn 51, Issue 9, 2010, Pages 1711-1719

  Griffiths, Elizabeth A ^a   Gore, Steven D ^a   Hooker, Craig ^a   McDevitt, Michael A ^b   Karp, Judith E ^a   Smith, B Douglas ^a   Mohammad, Helai P ^a   Ye, Ying ^a   Herman, James G ^a   Carraway, Hetty E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytogenetics; DNA methylation; epigenetics; leukemia; Wnt pathway

Indexed keywords

APC PROTEIN; BETA CATENIN; CYTARABINE; DAUNORUBICIN; DICKKOPF 1 PROTEIN; DICKKOPF 3 PROTEIN; ETOPOSIDE; FLUDARABINE; GLYCOPROTEIN; MITOXANTRONE; PROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SECRETED FRIZZLED RELATED PROTEIN 1; SECRETED FRIZZLED RELATED PROTEIN 2; SECRETED FRIZZLED RELATED PROTEIN 4; SECRETED FRIZZLED RELATED PROTEIN 5; TRANSCRIPTION FACTOR RUNX3; TRANSCRIPTION FACTOR SOX17; UNCLASSIFIED DRUG; WIF1 PROTEIN; WNT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; CYTOGENETICS; DNA METHYLATION; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPE; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; UPREGULATION;

AGED; BLOTTING, WESTERN; CELL LINE, TUMOR; COHORT STUDIES; DNA METHYLATION; EYE PROTEINS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; SURVIVAL RATE; WNT PROTEINS;

EID: 77956303152     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.496505     Document Type: Article

References (39)

1. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009;523-531.
2. Renneville A, Roumier C, Biggio V, et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 2008;22:915-931.
3. Steffen B, Muller-Tidow C, Schwable J, Berdel WE, Serve H. The molecular pathogenesis of acute myeloid leukemia. Crit Rev Oncol Hematol 2005;56:195-221.
4. Scholl C, Gilliland DG, Frohling S. Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol 2008;35: 336-345.
5. Moore MA. Converging pathways in leukemogenesis and stem cell self-renewal. Exp Hematol 2005;33:719-737.
6. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 2004;10:55-63.
7. Kielman MF, Rindapaa M, Gaspar C, et al. Apc modulates embryonic stem-cell differentiation by controlling the dosage of beta-catenin signaling. Nat Genet 2002;32:594-605.
8. Bovolenta P, Esteve P, Ruiz JM, Cisneros E, Lopez-Rios J. Beyond Wnt inhibition: new functions of secreted Frizzledrelated proteins in development and disease. J Cell Sci 2008;121:737-746.
9. Katoh M, Katoh M. WNT signaling pathway and stem cell signaling network. Clin Cancer Res 2007;13:4042-4045.
10. Moon RT, Bowerman B, Boutros M, Perrimon N. The promise and perils of Wnt signaling through beta-catenin. Science 2002;296:1644-1646.
11. Khan NI, Bendall LJ. Role of WNT signaling in normal and malignant hematopoiesis. Histol Histopathol 2006;21:761-774.
12. Valencia A, Roman-Gomez J, Cervera J, et al. Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia. Leukemia 2009;23: 1658-1666.
13. Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009;114:3448-3458.
14. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003;1653:1-24.
15. Licchesi JD, Westra WH, Hooker CM, Machida EO, Baylin SB, Herman JG. Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis 2008;29:895-904.
16. Serinsoz E, Neusch M, Busche G, Wasielewski R, Kreipe H, Bock O. Aberrant expression of beta-catenin discriminates acute myeloid leukaemia from acute lymphoblastic leukaemia. Br J Haematol 2004;126:313-319.
17. Simon M, Grandage VL, Linch DC, Khwaja A. Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia. Oncogene 2005;24:2410-2420.
18. Chung EJ, Hwang SG, Nguyen P, et al. Regulation of leukemic cell adhesion, proliferation, and survival by betacatenin. Blood 2002;100:982-990.
19. Ysebaert L, Chicanne G, Demur C, et al. Expression of betacatenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia 2006;20: 1211-1216.
20. Martin V, Valencia A, Agirre X, et al. Epigenetic regulation of the non-canonical Wnt pathway in acute myeloid leukemia. Cancer Sci 2010;101:425-432.
21. Xu J, Suzuki M, Niwa Y, et al. Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol 2008;140:394-401.
22. Tickenbrock L, Schwable J, Wiedehage M, et al. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. Blood 2005;105:3699-3706.
23. Dhir M, Montgomery EA, Glockner SC, et al. Epigenetic regulation of WNT signaling pathway genes in inflammatory bowel disease (IBD) associated neoplasia. J Gastrointest Surg 2008;12:1745-1753.
24. Klarmann GJ, Decker A, Farrar WL. Epigenetic gene silencing in the Wnt pathway in breast cancer. Epigenetics 2008;3:59-63.
25. Tolwinski NS, Wieschaus E. A nuclear function for armadillo/ beta-catenin. PLoS Biol 2004;2:E95.
26. Carraway HE, Wang S, Blackford A, et al. Promoter hypermethylation in sentinel lymph nodes as a marker for breast cancer recurrence. Breast Cancer Res Treat 2009;114: 315-325.
27. Easwaran HP, Schermelleh L, Leonhardt H, Cardoso MC. Replication- independent chromatin loading of Dnmt1 during G2 and M phases. EMBO Rep 2004;5:1181-1186.
28. Suzuki H, Watkins DN, Jair KW, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004;36:417-422.
29. Esteller M, Fraga MF, Guo M, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 2001;10:3001-3007.
30. Paz MF, Avila S, Fraga MF, et al. Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer Res 2002;62:4519-4524.
31. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-9826.
32. Karp JE, Smith BD, Levis MJ, et al. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res 2007;13:4467-4473.
33. Linker CA, Ries CA, Damon LE, et al. Autologous stem cell transplantation for acute myeloid leukemia in first remission. Biol Blood Marrow Transplant 2000;6:50-57.
34. Geller RB, Burke PJ, Karp JE, et al. A two-step timed sequential treatment for acute myelocytic leukemia. Blood 1989;74:1499-1506.
35. Bolanos-Meade J, Karp JE, Guo C, et al. Timed sequential therapy of acute myelogenous leukemia in adults: a phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin and etoposide. Leuk Res 2003;27: 313-321.
36. Majeti R, Becker MW, Tian Q, et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc Natl Acad Sci USA 2009;106: 3396-3401.
37. Jost E, Schmid J, Wilop S, et al. Epigenetic inactivation of secreted Frizzled-related proteins in acute myeloid leukaemia. Br J Haematol 2008;142:745-753.
38. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909-1918.
39. Minke KS, Staib P, Puetter A, et al. Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells. Eur J Haematol 2009;82: 165-175.